|
|
|
| Analysis of the Diagnostic Efficacy of Circulating OPN and miR-142-5p in Early Detection of Hepatocellular Carcinoma |
| REN Changrong, LIU Hui, ZHANG Kaiqian, et al |
| Chengde Medical University Affiliated Hospital / Hebei Key Laboratory of Panvascular Diseases, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To investigate the diagnostic value of osteopontin (OPN), miR-142-5p and AFP in primary hepatocellular carcinoma (HCC). Methods: A total of 40 patients with HCC, 30 patients with liver cirrhosis (LC), and 25 patients with chronic hepatitis (CH) in our hospital were selected as the research subjects. The levels of circulating OPN, miR-142-5p, and AFP were measured, and the receiver operating characteristic (ROC) curve of each index for the diagnosis of HCC was plotted. Results: OPN, miR-142-5p, and AFP demonstrated diagnostic efficacy for HCC when using patients with chronic liver diseases (CH + LC) as the benign control group. When they (OPN+miR-142-5p+AFP) were combined, the area under ROC was 0.935, and the sensitivity and specificity were 73.53% and 96.4%. Conclusion: OPN and miR-142-5p are potential biomarkers for the diagnosis of HCC. Their combination with AFP can improve the diagnostic sensitivity.
|
|
|
|
|
|
[1] Ganesan P,Kulik LM.Hepatocellular carcinoma:new developments[J].Clin Liver Dis,2023,27(1):85-102.
[2] Shan S,Jia J.The clinical management of hepatocellular carcinoma in China:Progress and challenges[J].Clin Mol Hepatol,2023,29(2):339-341.
[3] Lou K,Chen N,Li Z,et al.MicroRNA-142-5p overexpression inhibits cell growth and induces apoptosis by regulating FOXO in hepatocellular carcinoma Cells[J].Oncol Res,2024,32(9):1533.
[4] Zareifar P,Ahmed HM,Ghaderi P,et al.miR-142-3p/5p role in cancer:from epigenetic regulation to immunomodulation.[J].Cell Biochem Funct,2024,42(2):3931.
[5] Ramakrishnan K,Vishwakarma R,Dev RR,et al.Etiologically significant microRNAs in hepatitis B virus-induced hepatocellular carcinoma[J].OMICS,2024,28(6):280-290.
[6] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南年版[J].中华传染病杂志,2023,41(1):3-28.
[7] 中华医学会消化病学分会.中国肝硬化临床诊治共识意见[J].中华消化杂志,2023,43(4):227-247.
[8] 中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024年版)[J].协和医学杂志,2024,15(3):532-559.
[9] Xu L,Tian L,Yan Z,et al.Diagnostic and prognostic value of miR-486-5p,miR-451a,miR-21-5p and monocyte to high-density lipoprotein cholesterol ratio in patients with acute myocardial infarction[J].Heart Vessels,2023,38(3):318-331.
[10] Forner A,Reig M E,de Lope C R,et al.Current strategy for staging and treatment:the BCLC update and future prospects[J].Semin Liver Dis,2010,30(1):61-74.
[11] Kumari A,Kashyap D,Garg VK.Osteopontin in cancer[J].Adv Clin Chem,2024,118(1):87-110.
[12] Wu Q,Li L,Miao C,et al.Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production[J].Cell Death Dis,2022,13(4):341-341. |
|
|
|
2025, Vol. 31 
